Green Fertilizer Made with Air and Plasma: NitroCapt (Sweden) wins $2M Food Planet Prize 2025 for developing low-emission fertilizers
Nitrogen fertilizers are used for 50% of the world's food production and emit as much carbon dioxide as the aviation industry. Sweden-based NitroCapt has developed a novel, energy-efficient process that makes fertilizer through plasma-produced nitrate. NitroCapt's technology could improve access to green fertilizer across the world.
In awarding the Prize to NitroCapt, the Food Planet Prize jury Co-Chair Johan Rockström commented:
"Through NitroCapt's innovation, nitrogen fertilizer can now be produced by splitting nitrogen from the air with plasma technology simply needing green electricity as input. This technology reduces the use of energy tenfold, can be produced locally, avoids fossil-fuels entirely, while producing a nitrate fertilizer that can improve soil health and may be used sustainably by farmers across the world."
Gustaf Forsberg, CEO and Founder of NitroCapt, added:
"NitroCapt's mission is to decarbonize the nitrogen fertilizer industry. The current fossil-based process has reached its end point. We can also contribute to increased food production in areas that today have difficulties producing sufficient amounts. We are just about to finalize our industrial-scale pilot, and we have fertilizer in the field, but we're still not at the scale where we want to be.
This Prize will be very important for us to bring our technology to the stage where we can start making a difference."
About the Food Planet Prize The Curt Bergfors Food Planet Prize was established in Sweden in 2019, in acknowledgement of the perils that our current food systems pose to the health of people and the planet. The Prize supports initiatives that significantly reduce the environmental impact of the way we eat today. Unlike many awards, the Food Planet Prize recognizes initiatives for their potential future impact on the environment rather than past achievements. The Food Planet Prize's international jury consists of 10 leading specialists in complex Food Planet challenges. The jury is co-chaired by Johan Rockström and Magnus Nilsson.
For more information: press@foodplanetprize.org
NitroCapt Gustaf Forsberg, CEO and Founder gustaf.forsberg@nitrocapt.com
Photo - https://mma.prnewswire.com/media/2710491/Winner_of_the_Food_Planet_Prize_2025.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/green-fertilizer-made-with-air-and-plasma-nitrocapt-sweden-wins-2m-food-planet-prize-2025-for-developing-low-emission-fertilizers-302481115.html
SOURCE The Curt Bergfors Foundation - Food Planet Prize
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/13/c9485.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Breakthrough gene therapy jab reverses hearing loss in weeks
A single jab of a breakthrough gene therapy could reverse hearing loss in people within weeks, according to new research. The cutting-edge therapy improved hearing in children and adults with congenital deafness or severe hearing impairment, with a 7-year-old regaining almost full hearing in a clinical trial, researchers from Sweden's Karolinska Institutet said. The clinical trial, detailed in the journal Nature Medicine, showed that a healthy copy of the OTOF gene injected in the inner ear improved hearing of all 10 participants. The small-scale trial included people who had a genetic form of deafness or severe hearing impairment caused by mutations in a gene called OTOF. These mutations cause a deficiency of the protein otoferlin, which plays a key role in transmitting sound signals from the ear to the brain. While the therapy seemed to work best in children, researchers said, it could benefit adults as well. In the trial, a synthetic, harmless version of the adeno-associated virus was used to deliver a properly functional OTOF gene to the inner ear via a single injection. The effects of the therapy were evident in the majority of patients, whose hearing recovered rapidly after just a month. After six months, researchers noted considerable hearing improvement in all participants, with their average volume of perceptible sound improving from 106 decibels to 52. Those between the ages of five and eight responded best to the treatment, the study found. One seven-year-old girl quickly recovered almost all her hearing, and she was able to hold daily conversations with her mother four months afterwards. 'This is the first time that the method has been tested in teenagers and adults,' Maoli Duan, an author of the study from Karolinska Institutet, said. "Hearing was greatly improved in many of the participants, which can have a profound effect on their life quality. We will now be following these patients to see how lasting the effect is.' Researchers also found that the treatment was safe and well-tolerated. Participants did not report any serious adverse reactions in the follow-up period of 6-12 months. The most common reaction was a reduction in the number of the immune system's neutrophils, a type of white blood cell. "OTOF is just the beginning," Dr Duan said, adding that researchers were working on other common genes behind deafness such as GJB2 and TMC1. 'These are more complicated to treat, but animal studies have so far returned promising results. We are confident that patients with different kinds of genetic deafness will one day be able to receive treatment.'
Yahoo
2 hours ago
- Yahoo
Breakthrough gene therapy jab reverses hearing loss in weeks
A single jab of a breakthrough gene therapy could reverse hearing loss in people within weeks, according to new research. The cutting-edge therapy improved hearing in children and adults with congenital deafness or severe hearing impairment, with a 7-year-old regaining almost full hearing in a clinical trial, researchers from Sweden's Karolinska Institutet said. The clinical trial, detailed in the journal Nature Medicine, showed that a healthy copy of the OTOF gene injected in the inner ear improved hearing of all 10 participants. The small-scale trial included people who had a genetic form of deafness or severe hearing impairment caused by mutations in a gene called OTOF. These mutations cause a deficiency of the protein otoferlin, which plays a key role in transmitting sound signals from the ear to the brain. While the therapy seemed to work best in children, researchers said, it could benefit adults as well. In the trial, a synthetic, harmless version of the adeno-associated virus was used to deliver a properly functional OTOF gene to the inner ear via a single injection. The effects of the therapy were evident in the majority of patients, whose hearing recovered rapidly after just a month. After six months, researchers noted considerable hearing improvement in all participants, with their average volume of perceptible sound improving from 106 decibels to 52. Those between the ages of five and eight responded best to the treatment, the study found. One seven-year-old girl quickly recovered almost all her hearing, and she was able to hold daily conversations with her mother four months afterwards. 'This is the first time that the method has been tested in teenagers and adults,' Maoli Duan, an author of the study from Karolinska Institutet, said. "Hearing was greatly improved in many of the participants, which can have a profound effect on their life quality. We will now be following these patients to see how lasting the effect is.' Researchers also found that the treatment was safe and well-tolerated. Participants did not report any serious adverse reactions in the follow-up period of 6-12 months. The most common reaction was a reduction in the number of the immune system's neutrophils, a type of white blood cell. "OTOF is just the beginning," Dr Duan said, adding that researchers were working on other common genes behind deafness such as GJB2 and TMC1. 'These are more complicated to treat, but animal studies have so far returned promising results. We are confident that patients with different kinds of genetic deafness will one day be able to receive treatment.'
Business Insider
4 hours ago
- Business Insider
U.S. firm to build $1.5B power line linking Angola, DRC
U.S.-based energy company HYDRO-LINK has announced plans to construct a 1,150-kilometre electricity transmission line connecting Angola and the Democratic Republic of the Congo (DRC), in a step toward regional energy integration. HYDRO-LINK announced plans to construct a 1,150 km electricity transmission line between Angola and the DRC. The $1.5 billion project aims to alleviate power shortages in the DRC's Copperbelt mining region. The project is expected to be completed by 2029, also creating regional industrial and employment opportunities. The project, valued at $1.5 billion, addresses persistent power shortages in the DRC's southeastern Copperbelt region, which hosts critical mineral mines. With Angola enjoying a surplus of energy at its hydropower sites, the line will connect those sites to the DRC's energy-hungry mining areas. According to HYDRO-LINK, the transmission line is scheduled for completion by 2029. While it is primarily designed to power mining operations, the line will also connect to load centres in both Angola and the DRC, supplying much-needed electricity for public use. 'The transmission line will promote regional energy integration, provide energy security to the DRC, support the development of industrial hubs for local manufacturing and mineral processing, and create thousands of local construction jobs,' said Paul Hinks, CEO and Chairman of HYDRO-LINK. The project has taken a major step forward with the signing of a Memorandum of Understanding (MoU) with the Government of Angola. HYDRO-LINK also signed an MoU with the Swiss-based Mitrelli Group, which joins as a major investor and partner, and another with U.S.-based Sargent & Lundy, which will provide engineering services for the project. All three agreements were signed in Luanda during the U.S.-Africa Business Summit. According to HYDRO-LINK, the project will serve African and American strategic interests. Other strategic project partners HYDRO-LINK signed a memorandum of understanding with the Swiss-based Mitrelli Group, which has decades of operational experience in Angola and joins the project as a major investor and partner. Additionally, the company formalized an agreement with Sargent & Lundy, a U.S.-based architecture, engineering, and design firm, which will provide engineering services for the transmission line.
